[Secukinumab]

Ann Dermatol Venereol. 2019 Jun-Jul;146(6-7):503-506. doi: 10.1016/j.annder.2019.04.006. Epub 2019 Jun 14.

[Article in French]

Authors

L Meunier¹; Groupe de recherche sur le psoriasis de la Société française de dermatologie²

Affiliations

¹ Service de dermatologie, CHU, hôpital Carémeau, avenue du Pr Robert-Debré, 30029 Nîmes cedex, France. Electronic address: laurent.meunier@chu-nimes.fr.
² Service de dermatologie, CHU, hôpital Carémeau, avenue du Pr Robert-Debré, 30029 Nîmes cedex, France.

PMID: 31204124
DOI: 10.1016/j.annder.2019.04.006

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology*
Contraindications, Drug
Dermatologic Agents / pharmacology*
Drug Monitoring
Humans
Interleukin-17 / immunology
Psoriasis / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
Interleukin-17
secukinumab